Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia

被引:7
作者
Alcharakh, Mohammed [1 ]
Yun, Seongseok [2 ]
Dong, Yimin [3 ]
Vincelette, Nicole D. [4 ]
Daud, Madiha [1 ]
Manzoor, Saima [1 ]
Bin Riaz, Irbaz [1 ]
Anwer, Faiz [2 ,5 ]
机构
[1] Univ Arizona, Dept Med Hematol, Tucson, AZ 85721 USA
[2] Univ Arizona, Dept Med, Tucson, AZ 85721 USA
[3] Univ Arizona, Dept Pathol, Tucson, AZ 85721 USA
[4] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[5] Univ Arizona, Div Hematol Oncol Blood & Marrow Transplantat, Tucson, AZ 85721 USA
关键词
biphenotypic acute leukemia; blinatumomab; CD19; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; PHENOTYPE ACUTE-LEUKEMIA; TERM-FOLLOW-UP; B-LINEAGE; ANTIBODY BLINATUMOMAB; ADULT PATIENTS; FREE SURVIVAL; THERAPY; DEFINITION;
D O I
10.2217/imt-2015-0023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph+) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.
引用
收藏
页码:847 / 852
页数:6
相关论文
共 23 条
[1]   The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct [J].
Brandl, Christian ;
Haas, Cornelia ;
d'Argouges, Sandrine ;
Fisch, Tanja ;
Kufer, Peter ;
Brischwein, Klaus ;
Prang, Nadja ;
Bargou, Ralf ;
Suzich, JoAnn ;
Baeuerle, Patrick A. ;
Hofmeister, Robert .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) :1551-1563
[2]  
CLEMENTS P, 1995, J RHEUMATOL, V22, P1281
[3]   Tumor escape from immune response: Mechanisms and targets of activity [J].
Gabrilovich, D ;
Pisarev, V .
CURRENT DRUG TARGETS, 2003, 4 (07) :525-536
[4]   Salvage therapy for refractory or relapsed acute lymphocytic leukemia [J].
Garcia-Manero, G ;
Thomas, DA .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2001, 15 (01) :163-+
[5]   Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies [J].
Goekbuget, Nicola ;
Kneba, Michael ;
Raff, Thorsten ;
Trautmann, Heiko ;
Bartram, Claus-Rainer ;
Arnold, Renate ;
Fietkau, Rainer ;
Freund, Mathias ;
Ganser, Arnold ;
Ludwig, Wolf-Dieter ;
Maschmeyer, Georg ;
Rieder, Harald ;
Schwartz, Stefan ;
Serve, Hubert ;
Thiel, Eckhard ;
Brueggemann, Monika ;
Hoelzer, Dieter .
BLOOD, 2012, 120 (09) :1868-1876
[6]   Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab [J].
Klinger, Matthias ;
Brandl, Christian ;
Zugmaier, Gerhard ;
Hijazi, Youssef ;
Bargou, Ralf C. ;
Topp, Max S. ;
Goekbuget, Nicola ;
Neumann, Svenja ;
Goebeler, Mariele ;
Viardot, Andreas ;
Stelljes, Matthias ;
Brueggemann, Monika ;
Hoelzer, Dieter ;
Degenhard, Evelyn ;
Nagorsen, Dirk ;
Baeuerle, Patrick A. ;
Wolf, Andreas ;
Kufer, Peter .
BLOOD, 2012, 119 (26) :6226-6233
[7]   Graft-versus-leukemia reactions in allogeneic chimeras [J].
Kolb, HJ ;
Schmid, C ;
Barrett, AJ ;
Schendel, DJ .
BLOOD, 2004, 103 (03) :767-776
[8]  
Leo E, 2008, SCIENCE, V321, P974
[9]   Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation [J].
Loren, A. W. ;
Porter, D. L. .
BONE MARROW TRANSPLANTATION, 2008, 41 (05) :483-493
[10]  
Matutes E, 1997, HAEMATOLOGICA, V82, P64